Dr. Martens (DOCS) Trading update summary

Trading performance and outlook

• Trading since the start of the financial year has been in line with expectations, with no changes to FY27 guidance.

• Strategic objectives for FY27 remain on track, focusing on consumer, product, markets, and organisational improvements.

• The USA, the largest market, continues to grow, with particularly strong wholesale performance.

• Japan and South Korea are performing well, while European markets are meeting expectations despite a challenging consumer environment.

Strategic initiatives and brand positioning

• Aims to drive full price revenue mix in the UK and DACH regions.

• Plans to introduce an innovative new sandals range.

• Launching new retail concepts in key global cities.

• Focused on unlocking benefits from operating model and technology enhancements.

Brand and market presence

• Operates in over 60 countries with around 3,600 employees.

• Maintains heritage through 'Made in England' footwear and global production sites.

• Product range includes iconic boots, modern franchises, sandals, kids’ collection, and accessories.

• Listed on the London Stock Exchange and part of the FTSE 250 index.